The acquisition is expected to allow Rosetta Genomics to expeditedevelopment and validation of its microRNA-based diagnostic tests both in theU.S. and worldwide. In addition, ownership of the CLIA-certified lab willallow Rosetta Genomics to control the commercialization of its diagnostics,including marketing, sales, and reimbursement strategy. As previouslydisclosed, the first three of Rosetta Genomics' microRNA-based tests expectedto enter development and validation at Parkway's facilities this year:

- Differentiating squamous from non-squamous non-small cell lung cancer- This test is designed to differentiate squamous from non-squamous non-small cell lung cancer (NSCLC) using a single microRNA. The ability of physicians to accurately differentiate squamous from non-squamous NSCLC is an important treatment guide. Certain angiogenesis inhibitors for non-squamous NSCLC include a black-box warning about substantially higher rates of severe or fatal hemorrhage among patients with squamous NSCLC histology compared with non-squamous NSCLC. In addition, several other targeted drugs for NSCLC currently under development may require this sensitive differentiation. - Differentiating mesothelioma from adenocarcinoma - This differentiation is critical for optimal therapy, but is often difficult to perform. Currently, there is no objective, standardized test to aid pathologists in differentiating between the many possible tumors in the lung and pleura. Based on several microRNA biomarkers, this test is designed to separate mesothelioma from adenocarcinoma tumors including lung adenocarcinoma and metastases to the lung or to the pleura. - Identifying origin of metastases (CUP) - In 3%-5% of all new cancer patients, clinicians cannot identify the origin of a patients' tumor. This information is crucial for determining treatment type. As demonstrated in a paper published by Rosetta Genomics and collaborators in the April issue of Nature Biotechnology, Rosetta Genomics has developed a panel of microRNA biomarkers potentially able to identify approximately thirty cancer types. This test is designed to assist clinicians to accurately identify the origin of tumors. In addition, the company expects the following three tests to enterdevelopment during 2009-2010: response prediction to ovarian cancertreatment, predicting risk of gastric cancer recurrence, and differentiationof small cell from non-small cell lung cancer.

About MicroRNA

MicroRNAs (miRNAs) are recently discovered, naturally occurring, smallRNAs that act as master regulators and have the potential to form the basisfor a new class of diagnostics and therapeutics. Since many diseases arecaused by the abnormal activity of proteins, the ability to selectivelyregulate protein activity through microRNAs could provide the means to treata wide range of human diseases. In addition, microRNAs have been shown tohave different expression in various pathological conditions. As a result,these differences may provide for a novel diagnostic strategy for manydiseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA.Founded in 2000, the company's integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led to thediscovery of hundreds of biologically validated novel human microRNAs.Building on its strong IP position and proprietary platform technologies,Rosetta Genomics is working on the application of these technologies in thedevelopment of a full range of microRNA-based diagnostic and therapeutictools, focusing primarily on cancer and various women's health indications.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's futureexpectations, plans and prospects, including without limitation, statementsrelating to the completion of the acquisition of Parkway by Rosetta and theexpected impact of the acquisition will have on the commercialization ofRosetta's microRNA-based diagnostics, Parkway's expected revenues andoperating income for 2008, the role of microRNAs in human physiology anddisease, the potential of microRNAs in the diagnosis and treatment of diseaseand the expected timing of the development and commercialization ofdiagnostic tests using our microRNA technology constitute forward-lookingstatements for the purposes of the safe harbor provisions under The PrivateSecurities Litigation Reform Act of 1995. Actual results may differmaterially from those indicated by these forward-looking statements as aresult of various important factors, including risks related to: Rosetta'sapproach to discover microRNA technology and to work on the application ofthis technology in the development of novel diagnostics and therapeutictools, which is unproven and may never lead to marketable products orservices; Rosetta's ability to fund and the results of further pre-clinicaland clinical trials; Rosetta's ability to obtain, maintain and protect theintellectual property utilized by Rosetta's products; Rosetta's ability toenforce its patents against infringers and to defend its patent portfolioagainst challenges from third parties; Rosetta's ability to obtain additionalfunding to support its business activities; Rosetta's dependence on thirdparties for development, manufacture, marketing, sales, and distribution ofproducts; Rosetta's ability to successfully develop its candidate tools,products and services, all of which are in early stages of development;Rosetta's ability to obtain regulatory clearances or approvals that may berequired for its products and services; Rosetta's ability to obtain coverageand adequate payment from health insurers for the products and servicescomprising Rosetta's technology; competition from others using technologysimilar to Rosetta's and others developing products for similar uses;Rosetta's dependence on collaborators; and Rosetta's short operating history;as well as those risks more fully discussed in the "Risk Factors" section ofRosetta's Annual Report on Form 20-F for the year ended December 31, 2007, asfiled with the Securities and Exchange Commission. In addition, anyforward-looking statements represent Rosetta's views only as of the date ofthis release and should not be relied upon as representing its views as ofany subsequent date. Rosetta does not assume any obligation to update anyforward-looking statements unless required by law.

Contact: Media Rachel Spielman T: +1-212-583-2714 E: media@rosettagenomics.com Investors Ron Kamienchick T: +1-646-509-1893 E: investors@rosettagenomics.comSOURCE Rosetta Genomics Ltd